Rachel Ellingson

Chief Strategy & Corporate Development Officer · Solventum

Medical Devices and Healthcare Technology

Rachel Ellingson is Solventum’s chief strategy and corporate development officer. Her career spans healthcare investment banking, medical-device strategy, acquisitions and corporate administration.

Last reviewed: Nov 4, 2026

Rachel Ellingson

Chief Strategy & Corporate Development Officer
Solventum

Last Reviewed: November 4, 2026

Executive Summary

Rachel Ellingson is Solventum’s chief strategy and corporate development officer. Her career spans healthcare investment banking, medical-device strategy, acquisitions and corporate administration.

Career Highlights

  • Leads Solventum’s strategy and corporate development function.
  • Previously served as Zimmer Biomet’s chief administrative officer and chief strategy officer.
  • Joined BioLife Solutions’ board in April 2021.

Professional Journey

Ellingson began her career in investment banking, including work at Cowen & Company and subsequently Bank of America’s Healthcare Investment Banking Group, where she became a managing director. Her banking work focused on medical technology companies and financing and acquisition transactions.

She moved into operating-company leadership as vice president of Business Development and Investor Relations at AGA Medical. She subsequently served as vice president of Corporate Strategy at St. Jude Medical from 2011 through its acquisition by Abbott in 2017, participating in the company’s executive leadership team.

Ellingson joined Zimmer Biomet as senior vice president and chief strategy officer in April 2018. Her responsibilities included global strategy, business development and integration. She later became chief administrative officer, with oversight extending to separation management, marketing and communications.

At Solventum, she leads strategic direction and portfolio transformation, including acquisitions and divestitures intended to support the company’s growth plans.

Her professional board service includes joining BioLife Solutions in April 2021. The original appointment announcement described her experience executing more than 50 financing and M&A transactions during her career.

Education

Ellingson holds a Bachelor of Arts from the University of Rhode Island and an MBA in finance from the University of Connecticut.